What is DermBiont?
DermBiont is at the forefront of developing precision dermatology solutions, aiming to address the root causes of various skin conditions. The company's focus on targeted topical therapeutics positions it as a leader in a rapidly evolving sector. By leveraging advanced scientific approaches, DermBiont seeks to provide more effective and personalized treatment options for patients, differentiating itself in the competitive landscape of dermatological innovation.
How much funding has DermBiont raised?
DermBiont has raised a total of $71.3M across 4 funding rounds:
Series A
$8M
Debt
$150K
Series A
$28M
Series B
$35.2M
Series A (2019): $8M, investors not publicly disclosed
Debt (2020): $150K led by PPP
Series A (2021): $28M supported by Toba Capital, Viking Global Investors, Olive Tree Capital, and Civilization Ventures
Series B (2023): $35.2M featuring Civilization Ventures and Viking Global Investors
Key Investors in DermBiont
Civilization Ventures
Civilization Ventures is a venture capital firm specializing in health tech and biopharma, with a focus on preventative, personalized, and regenerative healthcare solutions. They have a strong track record of investing in innovative companies and supporting founders.
Viking Global Investors
Viking Global Investors is a global investment firm that employs research-intensive, long-term focused investment strategies across various industries and geographies, utilizing fundamental analysis for both public and private equity.
Toba Capital
Toba Capital is an early-stage investment firm that focuses on creating innovative technology companies with long-term growth potential, typically investing at the Seed and Series A stages in areas like SaaS and IT Infrastructure.
What's next for DermBiont?
With the recent major strategic investment and substantial overall capital, DermBiont is poised for significant expansion and further development of its therapeutic pipeline. The company is likely to accelerate its research and development efforts, potentially scale its operations, and advance its lead candidates through clinical trials. This strategic financing will enable DermBiont to solidify its market position and bring its innovative precision dermatology solutions to a wider patient population, marking a critical phase in its growth trajectory.
See full DermBiont company page
